| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Collaboration revenue | 1,741 | 1,629 | 3,074 | |
| Research and development | 25,838 | 29,136 | 34,650 | |
| General and administrative | 10,638 | 13,773 | 20,801 | |
| Total operating expenses | 36,476 | 42,909 | 55,451 | |
| Loss from operations | -34,735 | -41,280 | -52,377 | |
| Interest income | 2,575 | 3,336 | 4,438 | |
| Change in fair value of stock price appreciation milestones | 90 | -280 | 13 | |
| Other income | 0 | 43 | 274 | |
| Total other income | 2,485 | 3,659 | 4,699 | |
| Net loss | -32,250 | -37,621 | -47,678 | |
| Unrealized loss on available-for-sale securities, net | 91 | -77 | 1,257 | |
| Comprehensive loss | -32,159 | -37,698 | -46,421 | |
| Earnings per share, basic | -0.27 | -0.32 | -0.4 | |
| Earnings per share, diluted | -0.27 | -0.32 | -0.4 | |
| Weighted average number of shares outstanding, basic | 118,998,693 | 118,375,540 | 117,769,161 | |
| Weighted average number of shares outstanding, diluted | 118,998,693 | 118,375,540 | 117,769,161 | |
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)